JPRN-UMIN000049877RecruitingUnknown
Modulation of the antidepressant and antisuicidal efficacy of low-dose ketamine infusion via the mTORC1 modulator, Rapamycin: A double-blind, randomized, placebo controlled trial combined with the neuropsychological and functional connectivity MRI study. - Modulation of the antidepressant and antisuicidal efficacy of low-dose ketamine infusion via the mTORC1 modulator, Rapamycin
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Enrollment
- 48
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). (2) Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. (3) Pregnancy. (4) Substance abuse in previous 6 months such as cocaine, marijuana, opium, ketamine, PCP (phencyclidine). (5) Current use of NMDA receptor antagonist (Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan). (6) Alcohol abuse / dependence within 6 months. (7) Attempt suicide in hospital. (8) Allergy to ketamine or rapamycin.
Investigators
Similar Trials
Completed
Not Applicable
Antidepressant efficacy and mechanism of add-on cognitive activation to repetitive transcranial magnetic stimulation in depressioA randomized sham-controlled studyJPRN-UMIN000008421Taipei Veterans General Hospital36
Not yet recruiting
Phase 4
A clinical trial to study the effect of a combination therapy (oral ketamine and escitalopram) and escitalopram alone in elderly patient with depression, when given early in the course of treatment.CTRI/2023/04/051777King George Medical University
Not yet recruiting
Not Applicable
Clinical evaluation of the antidepressant effect of the use of probiotics in bipolar disorderRBR-5dhhhddniversidade de São Paulo
Completed
Not Applicable
Microdose Antagonist Combination for Depression (MAC-D) Trial: combination of low dose naltrexone and flumazenil for treatment of major depressive disorderMental Health - DepressionMajor Depressive DisorderACTRN12621000310864Trexapharm Pty Ltd10
Completed
Not Applicable
Are antidepressants more effective than placebo, when given in combination with mood stabilisers, in preventing mood episodes in people with bipolar I disorder?ISRCTN90111395niversity of British Columbia (Canada)216